Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers
Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited
Patients with specific PPP2R1A mutations...
MD Anderson achieves sixth Magnet designation in recognition of nursing excellence
Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center...

MD Anderson and HealthEx announce collaboration to develop new platform to give patients direct control of data access
The University of Texas MD Anderson Cancer Center and HealthEx today announced a strategic collaboration aimed at developing tools for...
Mailed self-collection HPV tests boost cervical cancer screening rates
Real-world study found self-collection tests were effective at increasing cervical cancer screening participation in underserved U.S. populations...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients...
ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
Most Americans unaware of cancer risks associated with drinking alcohol
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just 40%...